ZZPZH(SH:600436) Western Securities·2025-11-20 05:16Investment Rating - The investment rating for the company is "Accumulate" [4] Core Views - The company experienced a revenue decline of 11.93% year-on-year in Q1-Q3 2025, with a total revenue of 74.42 billion yuan and a net profit attributable to shareholders of 21.29 billion yuan, down 20.74% [1][4] - The decline in revenue and gross margin is expected to improve due to the decrease in the price of natural cow bile, which has dropped from 1.7 million yuan/kg to 1.4 million yuan/kg since June [1] - The company is focusing on its core product "Pianzaihuang" while expanding its product line and enhancing its research and development pipeline [2] Financial Performance Summary - For 2025, the company is projected to have an EPS of 4.04 yuan, with expected revenues of 9.764 billion yuan, a decrease of 9.5% from the previous year [3] - The gross margin for the pharmaceutical manufacturing segment is currently at 61.11%, down 9.68 percentage points [1] - The company has established strategic partnerships with major chain pharmacies, achieving coverage of over 100,000 stores [2]